List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/864889/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 2020, 182, 429-446.e14.	13.5	1,257
2	Targeting potential drivers of COVID-19: Neutrophil extracellular traps. Journal of Experimental Medicine, 2020, 217, .	4.2	1,193
3	Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood, 2020, 136, 1169-1179.	0.6	1,071
4	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	0.5	589
5	A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell, 2020, 27, 125-136.e7.	5.2	543
6	The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology, 2022, 17, 362-387.	0.5	429
7	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2013, 137, 647-667.	1.2	422
8	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	13.9	412
9	A molecular single-cell lung atlas of lethal COVID-19. Nature, 2021, 595, 114-119.	13.7	411
10	Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature, 2021, 589, 270-275.	13.7	389
11	COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. Modern Pathology, 2020, 33, 2156-2168.	2.9	380
12	Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension. Circulation: Cardiovascular Genetics, 2012, 5, 336-343.	5.1	333
13	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene Mutations. Journal of Clinical Oncology, 2016, 34, 794-802.	0.8	287
14	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2009, 133, 1317-1331.	1.2	268
15	The spatial landscape of lung pathology during COVID-19 progression. Nature, 2021, 593, 564-569.	13.7	249
16	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
17	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. Chest, 2007, 132, 998-1006.	0.4	223
18	Gene Expression in Wilms' Tumor Mimics the Earliest Committed Stage in the Metanephric Mesenchymal-Epithelial Transition. American Journal of Pathology, 2002, 160, 2181-2190.	1.9	213

#	Article	IF	CITATIONS
19	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212
20	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology, 2012, 25, 1574-1583.	2.9	206
21	Non-Small-Cell Lung Cancer Molecular Signatures Recapitulate Lung Developmental Pathways. American Journal of Pathology, 2003, 163, 1949-1960.	1.9	203
22	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
23	Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncology, The, 2021, 22, 824-835.	5.1	191
24	Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation, 2014, 94, 129-137.	1.7	188
25	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
26	Invasive Size is an Independent Predictor of Survival in Pulmonary Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 462-469.	2.1	178
27	EIF2AK4 Mutations in Pulmonary Capillary Hemangiomatosis. Chest, 2014, 145, 231-236.	0.4	176
28	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis, 2010, 31, 577-586.	1.3	158
29	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal of Clinical Investigation, 2017, 127, 2081-2090.	3.9	155
30	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature Communications, 2021, 12, 1660.	5.8	132
31	SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations after recovery. Science Translational Medicine, 2022, 14, .	5.8	129
32	SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metabolism, 2021, 33, 1577-1591.e7.	7.2	123
33	Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nature Medicine, 2018, 24, 770-781.	15.2	121
34	Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical and Experimental Metastasis, 2007, 24, 69-78.	1.7	118
35	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	0.5	113
36	Gene Expression in Lung Adenocarcinomas of Smokers and Nonsmokers. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 157-162.	1.4	112

#	Article	IF	CITATIONS
37	Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology, 2021, 88, 56-68.	1.9	111
38	Do all lung adenocarcinomas follow a stepwise progression?. Lung Cancer, 2011, 74, 7-11.	0.9	110
39	Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?. Modern Pathology, 2007, 20, 856-863.	2.9	107
40	Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 341-344.	1.2	107
41	Molecular Signatures in Biopsy Specimens of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 167-174.	2.5	105
42	Computer-aided diagnosis of pulmonary nodules using a two-step approach for feature selection and classifier ensemble construction. Artificial Intelligence in Medicine, 2010, 50, 43-53.	3.8	104
43	A Molecular Profile of Focal Segmental Glomerulosclerosis from Formalin-Fixed, Paraffin-Embedded Tissue. American Journal of Pathology, 2010, 177, 1674-1686.	1.9	104
44	The Heparan Sulfate ProteoglycanGPC3Is a Potential Lung Tumor Suppressor. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 694-701.	1.4	97
45	Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1267-1272.	1.2	95
46	A Postinfluenza Model of <i>Staphylococcus aureus</i> Pneumonia. Journal of Infectious Diseases, 2010, 201, 508-515.	1.9	89
47	Genome-wide DNA methylation profiling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. Journal of Leukocyte Biology, 2021, 110, 21-26.	1.5	82
48	PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis, 2013, 34, 739-749.	1.3	81
49	Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer, 2004, 101, 1632-1638.	2.0	78
50	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. Clinical Cancer Research, 2017, 23, 825-832.	3.2	78
51	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	1.4	78
52	Lung Adenocarcinoma Global Profiling Identifies Type II Transforming Growth Factor-Î ² Receptor as a Repressor of Invasiveness. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 729-737.	2.5	77
53	Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget, 2016, 7, 28976-28988.	0.8	74
54	Well-differentiated Papillary Mesothelioma With Invasive Foci. American Journal of Surgical Pathology, 2014, 38, 990-998.	2.1	72

#	Article	IF	CITATIONS
55	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2018, 142, 408-419.	1.2	70
56	CDX2 Immunostaining as a Gastrointestinal Marker. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 55-60.	0.6	69
57	Lung Pathologic Findings in a Local Residential and Working Community Exposed to World Trade Center Dust, Gas, and Fumes. Journal of Occupational and Environmental Medicine, 2011, 53, 981-991.	0.9	68
58	Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival. Cancer, 2011, 117, 2186-2191.	2.0	67
59	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers. Clinical Cancer Research, 2018, 24, 1954-1964.	3.2	64
60	Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. Archives of Pathology and Laboratory Medicine, 2018, 142, 236-242.	1.2	61
61	P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma. Clinical Cancer Research, 2005, 11, 3303-3308.	3.2	59
62	Gene Expression Profiling of Pulmonary Fibrosis Identifies Twist1 as an Antiapoptotic Molecular "Rectifier―of Growth Factor Signaling. American Journal of Pathology, 2009, 175, 2351-2361.	1.9	55
63	TGF-² Signaling Pathway in Lung Adenocarcinoma Invasion. Journal of Thoracic Oncology, 2010, 5, 153-157.	0.5	55
64	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
65	Sarcoidosis-Associated Fibrosing Mediastinitis with Resultant Pulmonary Hypertension: A Case Report and Review of the Literature. Respiration, 2010, 79, 341-345.	1.2	54
66	Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non–Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. Archives of Pathology and Laboratory Medicine, 2013, 137, 32-40.	1.2	54
67	Comparative Anatomy of Chromosomal Domains with Imprinted and Non-Imprinted Allele-Specific DNA Methylation. PLoS Genetics, 2013, 9, e1003622.	1.5	47
68	Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology and Therapy, 2016, 17, 328-335.	1.5	47
69	Pulmonary pathology of COVID-19: a review of autopsy studies. Current Opinion in Pulmonary Medicine, 2021, 27, 184-192.	1.2	47
70	Histologic Assessment of Non-Small Cell Lung Carcinoma after Neoadjuvant Therapy. Modern Pathology, 2003, 16, 1102-1108.	2.9	46
71	Epigenetic Inactivation of Betaig-h3 Gene in Human Cancer Cells. Cancer Research, 2006, 66, 4566-4573.	0.4	46
72	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Science Translational Medicine, 2016, 8, 350ra104.	5.8	45

#	Article	IF	CITATIONS
73	Cytokine-Like Factor 1 Gene Expression Is Enriched in Idiopathic Pulmonary Fibrosis and Drives the Accumulation of CD4+ T Cells in Murine Lungs. American Journal of Pathology, 2012, 180, 1963-1978.	1.9	42
74	Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. Modern Pathology, 2012, 25, S1-S10.	2.9	40
75	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. Circulation Research, 2021, 129, 33-46.	2.0	40
76	Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. European Respiratory Review, 2016, 25, 364-371.	3.0	39
77	Use of Oncogenic Driver Mutations in Staging ofÂMultiple Primary Lung Carcinomas: A Single-Center Experience. Journal of Thoracic Oncology, 2017, 12, 1524-1535.	0.5	39
78	Sebaceous Carcinoma of the Lung: Histologic and Immunohistochemical Characterization of an Unusual Pulmonary Neoplasm. American Journal of Surgical Pathology, 2002, 26, 795-798.	2.1	38
79	Platelet-Derived Growth Factor Is Increased in Pulmonary Capillary Hemangiomatosis. Chest, 2007, 131, 850-855.	0.4	38
80	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secretingÂCCL2. Stem Cell Reports, 2021, 16, 2274-2288.	2.3	37
81	Genomics of Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 152-158.	3.5	36
82	Bi-allelic Mutations in Phe-tRNA Synthetase Associated with a Multi-system Pulmonary Disease Support Non-translational Function. American Journal of Human Genetics, 2018, 103, 100-114.	2.6	34
83	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	0.5	33
84	Progression of Human Bronchioloalveolar Carcinoma to Invasive Adenocarcinoma Is Modeled in a Transgenic Mouse Model of K-ras–Induced Lung Cancer by Loss of the TGF-β Type II Receptor. Cancer Research, 2011, 71, 6665-6675.	0.4	32
85	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	32
86	Genomic Underpinnings of Tumor Behavior in <i>In Situ</i> and Early Lung Adenocarcinoma. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 697-706.	2.5	32
87	Tissue factor upregulation is associated with SARSâ€CoVâ€2 in the lungs of COVIDâ€19 patients. Journal of Thrombosis and Haemostasis, 2021, 19, 2268-2274.	1.9	32
88	Genome-wide association study of subclinical interstitial lung disease in MESA. Respiratory Research, 2017, 18, 97.	1.4	31
89	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. Archives of Pathology and Laboratory Medicine, 2020, 144, 1392-1396.	1.2	31
90	L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus. JCI Insight, 2021, 6, .	2.3	31

#	Article	IF	CITATIONS
91	Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer, 2003, 39, 23-29.	0.9	30
92	Fine needle aspiration biopsy of epithelioid hemangioendothelioma of the oral cavity: Report of one case and review of literature. Diagnostic Cytopathology, 2006, 34, 218-223.	0.5	30
93	Utility of Glucose Transporter 1 in the Distinction of Benign and Malignant Thoracic and Abdominal Mesothelial Lesions. Archives of Pathology and Laboratory Medicine, 2012, 136, 804-809.	1.2	30
94	Expression Profiling and Lung Cancer Development. Proceedings of the American Thoracic Society, 2007, 4, 127-132.	3.5	29
95	Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, 628-635.	1.5	28
96	Prevalence and Mechanisms of Mucus Accumulation in COVID-19 Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1336-1352.	2.5	28
97	Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology, 2016, 68, 729-737.	1.6	26
98	Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 2016, 140, 1281-1284.	1.2	26
99	Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes. Journal of Clinical Pathology, 2018, 71, 626-630.	1.0	26
100	Cryobiopsy in the Diagnosis of Interstitial Lung Disease. A Step Forward or Back?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 707-709.	2.5	25
101	An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 2016, 5, 2641-2648.	1.3	25
102	Insulinoma-associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2019, 8, 299-308.	0.2	25
103	Cytological, histological, and immunohistochemical findings of pulmonary carcinomas with basaloid features. Diagnostic Cytopathology, 2011, 39, 92-100.	0.5	24
104	Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Archives of Pathology and Laboratory Medicine, 2016, 140, 1104-1110.	1.2	24
105	Uncommon Types of Lung Carcinoma With Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 914-921.	1.2	24
106	Clinical significance of blueâ€green neutrophil and monocyte cytoplasmic inclusions in SARS oVâ€⊋ positive critically ill patients. British Journal of Haematology, 2020, 190, e89-e92.	1.2	24
107	Cytokine signatures of end organ injury in COVID-19. Scientific Reports, 2021, 11, 12606.	1.6	24
108	PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget, 2018, 9, 24914-24926.	0.8	24

#	Article	IF	CITATIONS
109	System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell Reports Medicine, 2022, 3, 100522.	3.3	24
110	Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagnostic Cytopathology, 2005, 33, 65-70.	0.5	23
111	Recent advances in the management of pulmonary sarcomatoid carcinoma. Expert Review of Respiratory Medicine, 2016, 10, 407-416.	1.0	23
112	MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies. Expert Opinion on Therapeutic Targets, 2021, 25, 249-268.	1.5	22
113	Benign Tumors and Tumorlike Conditions of the Lung. Archives of Pathology and Laboratory Medicine, 2008, 132, 1133-1148.	1.2	22
114	Pleomorphic (Spindle and Squamous Cell) Carcinoma Arising in a Peripheral Mixed Squamous and Glandular Papilloma in a 70-Year-Old Man. Archives of Pathology and Laboratory Medicine, 2011, 135, 1353-1356.	1.2	21
115	Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. European Respiratory Journal, 2013, 41, 1324-1330.	3.1	20
116	Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. American Journal of Pathology, 2022, 192, 1001-1015.	1.9	19
117	Pulmonary Capillary Hemangiomatosis. Chest, 2005, 128, 575S-576S.	0.4	18
118	Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2007, 37, 193-201.	1.4	18
119	Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Modern Pathology, 2013, 26, 239-246.	2.9	18
120	Pulmonary Pathology Society Perspective on the 2018 American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society Idiopathic Pulmonary Fibrosis Clinical Practice Guidelines. Annals of the American Thoracic Society, 2020, 17, 550-554	1.5	17
121	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non–small cell lung cancer. Science Translational Medicine, 2022, 14, eabe8195.	5.8	16
122	Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. Nature Communications, 2022, 13, 1592.	5.8	16
123	A Two-Step Approach for Feature Selection and Classifier Ensemble Construction in Computer-Aided Diagnosis. , 2008, , .		15
124	Elastin in pulmonary pathology: relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint. Histopathology, 2022, 80, 457-467.	1.6	15
125	Global evolution of the tumor microenvironment associated with progression from preinvasive invasive human lung adenocarcinoma. Cell Reports, 2022, 39, 110639.	2.9	15
126	Pulmonary Neuroendocrine Tumors. Surgical Pathology Clinics, 2020, 13, 35-55.	0.7	14

#	Article	IF	CITATIONS
127	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. Archives of Pathology and Laboratory Medicine, 2020, 144, 1477-1489.	1.2	14
128	Updates in grading and invasion assessment in lung adenocarcinoma. Modern Pathology, 2022, 35, 28-35.	2.9	14
129	Silicosis in dental supply factory workers. Respiratory Medicine, 2004, 98, 791-794.	1.3	13
130	Pulmonary Kirsten Rat Sarcoma Virus Mutation Positive Mucinous Adenocarcinoma Arising in aÂCongenital Pulmonary AirwayÂMalformation, Mixed Type 1 and 2. Annals of Thoracic Surgery, 2016, 102, e335-e337.	0.7	13
131	Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2019, 8, 39-46.	0.2	13
132	Utility of Claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma. Journal of the American Society of Cytopathology, 2020, 9, 146-151.	0.2	13
133	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	0.5	13
134	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. Archives of Pathology and Laboratory Medicine, 2016, 140, 351-354.	1.2	12
135	MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 7084-7096.	3.2	12
136	Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. EBioMedicine, 2022, 77, 103894.	2.7	12
137	Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination. Cancer Research, 2022, 82, 1365-1379.	0.4	11
138	Challenges of Frozen Section in Thoracic Pathology: Lepidic Lesions, Limited Resections, and Margins. Archives of Pathology and Laboratory Medicine, 2017, 141, 932-939.	1.2	10
139	Reproducibility for histologic parameters in peritoneal mesothelioma. Human Pathology, 2017, 67, 54-59.	1.1	10
140	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. Archives of Pathology and Laboratory Medicine, 2020, 144, 1535-1546.	1.2	10
141	Neoplastic and Nonneoplastic Benign Mass Lesions of the Lung. Archives of Pathology and Laboratory Medicine, 2012, 136, 1227-1233.	1.2	9
142	Thoracoscopic lobectomy for type I pleuropulmonary blastoma in an infant. Pediatric Surgery International, 2014, 30, 239-242.	0.6	8
143	Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists. Annals of Diagnostic Pathology, 2019, 41, 43-50.	0.6	8
144	Early-Stage Lung Adenocarcinoma MDM2 Genomic Amplification Predicts Clinical Outcome and Response to Targeted Therapy. Cancers, 2022, 14, 708.	1.7	8

#	Article	IF	CITATIONS
145	Micropapillary Histology. American Journal of Clinical Pathology, 2009, 131, 615-617.	0.4	7
146	Nextâ€generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study. Cancer Cytopathology, 2020, 128, 840-851.	1.4	6
147	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	0.5	6
148	Unbalanced t(2;19) and t(2;16) in a neurofibroma. Cancer Genetics and Cytogenetics, 2004, 152, 169-171.	1.0	5
149	A SECONDARY CARE PERSPECTIVE ON THE STEPPING-DOWN OF INHALED CORTICOSTEROID THERAPY IN PATIENTS WITH STABLE ASTHMA. Chest, 2005, 128, 242S.	0.4	4
150	Has MET met its match?. Annals of Translational Medicine, 2016, 4, 97-97.	0.7	4
151	Class Prediction of Lung Nodule Gene Expression Profiles. Chest, 2004, 125, 104S.	0.4	3
152	Impact of segmentation uncertainties on computer-aided diagnosis of pulmonary nodules. International Journal of Computer Assisted Radiology and Surgery, 2008, 3, 551-558.	1.7	3
153	Higher Tissue Factor (TF) Expression in the Lungs of COVID-19 Pneumonia Patients Than Patients with Acute Respiratory Distress Syndrome: Association with Thrombi Formation. Blood, 2020, 136, 4-4.	0.6	3
154	Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition Journal of Clinical Oncology, 2015, 33, 8020-8020.	0.8	3
155	A case series on inflammatory cardiomyopathy and suspected cardiac sarcoidosis: role of cardiac PET in management. European Heart Journal - Case Reports, 2020, 4, 1-9.	0.3	2
156	Genomic Alterations in Pulmonary Adenocarcinoma In Situ in an Adolescent Patient. Archives of Pathology and Laboratory Medicine, 2014, 138, 559-563.	1.2	1
157	Over- and Underdiagnosis in Lung Cancer: Searching for a "Solid―Diagnosis. Radiology, 2016, 280, 655-658.	3.6	1
158	Routine molecular testing of resected early-stage lung adenocarcinoma with targeted next-generation sequencing demonstrates a high rate of actionable mutations. Journal of Thoracic Oncology, 2016, 11, S44-S45.	0.5	1
159	Focusing on Preinvasive Neoplasia: A Molecular Frontier at the Pathologist's Fingertips. Archives of Pathology and Laboratory Medicine, 2017, 141, 1604-1605.	1.2	1
160	Keeping Up With Testing Guidelines in Lung Cancer. Archives of Pathology and Laboratory Medicine, 2018, 142, 783-784.	1.2	1
161	Chondroid lipoma: multimodality imaging in a 9-year-old female. Skeletal Radiology, 2020, 49, 161-169.	1.2	1
162	The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. Journal of the American Society of Cytopathology, 2020, 9, 55-61.	0.2	1

#	Article	IF	CITATIONS
163	Therapeutic Interception of Early Lung Adenocarcinoma Progression: Not Just How, but When?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 8-9.	2.5	1
164	Abstract 4690: PARP inhibition increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancers. , 2012, , .		1
165	Alain C. Borczuk, MD, Assumes Editorship of Archives. Archives of Pathology and Laboratory Medicine, 2021, 145, 10-10.	1.2	1
166	Non-small Cell Lung Cancer Molecular Profiles Are Associated With Lung Development. Chest, 2004, 125, 115S-116S.	0.4	0
167	ENDOBRONCHIAL SCLEROSIS OF PULMONARY PARENCHYMA IN RATS. Chest, 2007, 132, 520A.	0.4	Ο
168	Chronic Inflammation Promotes Tobacco Carcinogen Associated Tumors In Lung Cancer Susceptible (A/J) And Resistant (B6) Mice. , 2010, , .		0
169	Hypersensitivity Pneumonitis In A 20-month-old Child Due To Mycobacterium Avium Complex. , 2010, , .		0
170	CCR5 Small Molecule Inhibitors Reduce Invasion And Migration Of Lung Adenocarcinoma Cells. , 2010, ,		0
171	Stromal Cell Gene Signature Of Lung Adenocarcinoma Invasion. , 2010, , .		0
172	Loss Of The Transforming Growth Factor-Beta (TGF-) Receptor In The Mutated K-RAS Orthotopic Model Of Murine Lung Cancer Parallels The Progression Of Human Bronchioloalveolar Cell Carcinoma To Invasive Adenocarcinoma. , 2011, , .		0
173	Cpap In The Management Of A 5-Month-Old With Late Clinical Presentation Of Primary Pulmonary Lymphangiectasia. , 2011, , .		Ο
174	Cytokine-Like Factor I (CLF1) Expression Is Increased In Idiopathic Pulmonary Fibrosis (IPF) And Promotes Inflammation But Decreases Fibrosis In Bleomycin Injury. , 2011, , .		0
175	Drug Induced Non-Specific Interstitial Pneumonitis. , 2011, , .		0
176	Diagnostic Patient Care, Not Just Diagnosis. Archives of Pathology and Laboratory Medicine, 2012, 136, 711-712.	1.2	0
177	Molecular Basis for the Current Lung Cancer Classification. Molecular Pathology Library, 2012, , 75-85.	0.1	0
178	A Man in His 20s With Cough, Unilateral Pleural Effusion, and Nodular Pleural Thickening. Chest, 2019, 156, e121-e126.	0.4	0
179	Frozen Section in Lung and Pleural Pathology. , 2021, , 225-245.		0
180	Molecular Pathology of Large Cell Carcinoma and Its Precursors. Molecular Pathology Library, 2008, , 279-292.	0.1	0

#	Article	IF	CITATIONS
181	Molecular Pathology of Large Cell Carcinoma. Molecular Pathology Library, 2012, , 169-183.	0.1	Ο
182	In situ distribution of metallic platinum in tumor tissues after intraperitoneal platinum chemotherapy assessed by digital synchrotron-abetted x-ray fluorescence microscopy Journal of Clinical Oncology, 2012, 30, e13067-e13067.	0.8	0
183	Abstract LB-46: C/EBPα acts as tumor suppressor in lung cancer by inhibiting the proto-oncogene Bmi-1 , 2013, , .		0
184	Exploring therapeutic targets in pulmonary sarcomatoid carcinoma by comprehensive genomic profiling Journal of Clinical Oncology, 2014, 32, 8073-8073.	0.8	0
185	A two-stage, open-label, phase II study of bortezomib plus oxaliplatin in previously treated patients with malignant pleural or peritoneal mesothelioma Journal of Clinical Oncology, 2014, 32, e22191-e22191.	0.8	0
186	Abstract 3526: The mTORC2 component RICTOR plays a key role in lung cancer cell growth. , 2014, , .		0
187	Long-term outcomes of cytoreduction and HIPEC for malignant peritoneal mesothelioma Journal of Clinical Oncology, 2015, 33, 4111-4111.	0.8	0
188	Abstract 5329: Development of small molecule activators of protein phosphatase 2A for the treatment of lung cancer. , 2015, , .		0
189	Abstract 696: Comprehensive genomic analysis identifies frequent MET juxtamembrane domain deletions as an actionable genomic alteration in pulmonary sacromatoid carcinoma. , 2015, , .		0
190	Abstract 3865: Therapeutic activation of protein phosphatase 2A for the treatment of lung cancer. , 2016, , .		0
191	Abstract 1217: Blockade of Aurora kinase A synergizes with platinum and radiation in non-small cell lung cancer cells. , 2017, , .		0
192	Precursor and Preinvasive Lesions. Molecular Pathology Library, 2018, , 213-231.	0.1	0
193	Molecular Pathology of Uncommon Carcinomas. Molecular Pathology Library, 2018, , 183-197.	0.1	0
194	Sarcomatous Diffuse Malignant Mesothelioma, Pleural. Encyclopedia of Pathology, 2018, , 367-374.	0.0	0